Pliant Therapeutics Inc - PLRX EV/Sales Multiple

Public company logo of Pliant Rx (PLRX)

The professionalism of Bernard Coulson's team is driving growth, and the aggregate chart on GURU.Markets displays the EV/Sales trajectory, where 0.00 indicates the level of this metric for Pliant Therapeutics (PLRX). The business foundation relies on unique selective integrin inhibition to combat fibrosis. Stable demand is ensured by the necessity for long-term therapy, guaranteeing the multi-year viability of the company's drugs.

Pliant Therapeutics, Inc. - PLRX Enterprise Value-to-Revenue Ratio (period 11/23/2025 - 11/20/2026)

PLRX (Pliant Therapeutics): analytical breakdowns and indicator data

Initial company analysis:Pliant Therapeutics Inc - PLRX
Mass-produced product of Pliant Rx

This indicator determines the market value of the business, accounting for net debt per unit of revenue, allowing for an assessment of the asset's investment attractiveness regardless of financial leverage. By analyzing the enterprise value-to-revenue ratio, an investor can see the sensitivity of Pliant Therapeutics (PLRX) capitalization to successes in fibrosis therapy, where future cash flows depend on clinical efficacy and the ability to attract resources.